What does Fermenta Biotec. do?

Fermenta Biotech Limited manufactures and markets chemicals, bulk drugs, enzymes, and pharmaceutical formulations, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of ₹140 Cr and a net profit of ₹34 Cr, with a market cap of ₹948 Cr.

Overview: <BR>Fermenta Biotech Limited is engaged in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Fermenta Biotech Limited was incorporated in May 1951 as 'Duphar-Interfran Limited', changed its name to 'DIL Limited' in September 2003, and was renamed 'Fermenta Biotech Limited' on October 17, 2019. The most recent quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 140 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 34 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 948 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 12.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.39% <BR>Debt-Equity: 0.12 <BR>Return on Equity: 21.19% <BR>Price to Book: 2.62 <BR><BR>Contact Details: <BR>Address: A-1501 DIL Complex Majiwada, Ghodbunder Road Thane One Thane (West) Maharashtra : 400610 <BR>Tel: 91-22-66230800/888 <BR>Email: srikant.sharma@dil.net; contact@dil <BR>Website: http://www.fermentabiotech.com

Who are in the management team of Fermenta Biotec.?

As of March 2022, the management team of Fermenta Biotec includes Satish Varma (Executive Director), Krishna Datla (Executive Chairman), Prashant Nagre (Managing Director), and several independent directors, among others. The team features a mix of executive and compliance roles.

As of March 2022, the management team of Fermenta Biotec includes the following individuals:<BR><BR>1. **Satish Varma** - Executive Director<BR>2. **Srikant N Sharma** - Company Secretary & Compliance Officer<BR>3. **Krishna Datla** - Executive Chairman & Whole-Time Director<BR>4. **Rajeshwari Datla** - Director<BR>5. **Sanjay Buch** - Chairman & Independent Director<BR>6. **Vinayak Hajare** - Independent Director<BR>7. **Gopakumar G Nair** - Independent Director<BR>8. **Anupama Datla Desai** - Executive Director<BR>9. **Rajashri Santosh Kumar Ojha** - Independent Director<BR>10. **Prashant Nagre** - Managing Director<BR>11. **Pramod Kasat** - Independent Director<BR><BR>This diverse team encompasses various roles, including executive, independent, and compliance positions.

What is the bonus history of the Fermenta Biotec.?

Fermenta Biotec has issued bonuses twice in recent years: a 2:1 bonus on February 13, 2020, and a 1:1 bonus on August 8, 2018, reflecting a consistent practice of rewarding shareholders.

Fermenta Biotec has a history of bonus issues that includes two significant events. The latest bonus was a 2:1 issue announced on February 13, 2020, with a record date of February 14, 2020. Prior to that, the company issued a 1:1 bonus on August 8, 2018, with a record date of August 9, 2018. This indicates a pattern of rewarding shareholders through bonus shares in recent years.

Has Fermenta Biotec. declared dividend?

Fermenta Biotech Ltd has declared a 25% dividend, amounting to ₹1.25 per share, with an ex-date of August 6, 2024. While the dividend yield is 0.39%, total returns have been notably positive over the 1-year (103.61%) and 2-year (130.15%) periods.

Fermenta Biotech Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 1.25<BR>- Ex-date: 06 Aug 24<BR><BR>Dividend Yield: 0.39%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -20.96%, the dividend return was 0%, resulting in a total return of -20.96%.<BR><BR>For the 1-year period, the price return was 102.83%, the dividend return was 0.78%, leading to a total return of 103.61%.<BR><BR>Over the 2-year period, the price return was 128.37%, the dividend return was 1.78%, culminating in a total return of 130.15%.<BR><BR>In the 3-year period, the price return was 58.35%, the dividend return was 1.97%, which resulted in a total return of 60.32%.<BR><BR>During the 4-year period, the price return was -0.37%, the dividend return was 1.89%, giving a total return of 1.52%.<BR><BR>For the 5-year period, the price return was 30.76%, the dividend return was 2.40%, resulting in a total return of 33.16%.<BR><BR>Overall, Fermenta Biotech Ltd has declared a dividend, and while the dividend yield is relatively low, the total returns over longer periods show significant positive growth, particularly in the 1-year and 2-year periods.

Who are the peers of the Fermenta Biotec.?

Fermenta Biotec's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Kopran, Bharat Parenter, Shree Ganesh Rem, Kilitch Drugs, and NGL Fine Chem. In terms of performance, Fermenta Biotec has a 1-year return of 105.43%, significantly higher than its peers, while management and growth ratings vary across the group.

Peers: The peers of Fermenta Biotec. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Kopran, Bharat Parenter., Shree Ganesh Rem, Kilitch Drugs, and NGL Fine Chem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Bharat Parenter., Shree Ganesh Rem, and Kopran, and the rest have Below Average management risk. Growth is Excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Kilitch Drugs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Kopran, Fermenta Biotec., Bharat Parenter., and NGL Fine Chem, and Average growth is seen at Shree Ganesh Rem. In terms of Capital Structure, Excellent ratings are given to Sun Pharma.Inds., Divi's Lab., Cipla, and Shree Ganesh Rem, Good ratings to Torrent Pharma and Kilitch Drugs, Average ratings to Bharat Parenter. and Kopran, and Below Average to Fermenta Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is NGL Fine Chem at -52.32%. Fermenta Biotec. has a 1-year return of 105.43%, which is significantly higher than all peers. Additionally, the peers with negative six-month returns include Kopran, Bharat Parenter., Shree Ganesh Rem, and NGL Fine Chem.

Who are the top shareholders of the Fermenta Biotec.?

The top shareholders of Fermenta Biotec include promoter Krishna Datla with 36.04%, individual investors holding 30.38%, and public shareholder Rakesh Kantilal Shah with 2.04%. There are no pledged promoter holdings, and foreign institutional investors hold a total of 0.02%.

The top shareholders of Fermenta Biotec include the promoters, with Krishna Datla holding the highest share at 36.04%. There are no pledged promoter holdings, and individual investors collectively hold 30.38% of the shares. Additionally, Rakesh Kantilal Shah is the highest public shareholder with a stake of 2.04%. The company also has two foreign institutional investors (FIIs) holding a total of 0.02%.

How big is Fermenta Biotec.?

As of 24th July, Fermenta Biotech Ltd has a market capitalization of 1,116.00 Cr, with recent net sales of 469.48 Cr and a net profit of 76.86 Cr. Shareholder's funds are 362.67 Cr, and total assets are valued at 585.83 Cr.

As of 24th July, Fermenta Biotech Ltd has a market capitalization of 1,116.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 469.48 Cr and a Net Profit of 76.86 Cr.<BR><BR>As of March 2025, the Shareholder's Funds amounted to 362.67 Cr, while the Total Assets were valued at 585.83 Cr.

When is the next results date for Fermenta Biotec.?

Fermenta Biotec is scheduled to announce its results on 12 August 2025.

Fermenta Biotec is scheduled to declare its results on 12 August 2025.

Is Fermenta Biotec. overvalued or undervalued?

As of October 1, 2025, Fermenta Biotec is considered very attractive for investment due to its undervalued status, highlighted by a PE ratio of 9.21 and strong growth potential, despite a recent decline in stock performance compared to the Sensex.

As of 1 October 2025, the valuation grade for Fermenta Biotec has moved from attractive to very attractive, indicating a strong improvement in its investment appeal. The company is currently assessed as undervalued, supported by a PE ratio of 9.21, an EV to EBITDA of 7.33, and a PEG ratio of 0.02, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, Fermenta Biotec's valuation metrics stand out; for instance, Sun Pharma has a PE ratio of 34.22 and an EV to EBITDA of 23.17, while Cipla shows a PE of 22.63 and an EV to EBITDA of 15.9, both indicating higher valuations than Fermenta. Notably, Fermenta's ROCE and ROE are strong at 21.08% and 21.19%, respectively, further reinforcing its undervalued status. Despite a recent decline in stock performance compared to the Sensex, with a YTD return of -10.15% versus the Sensex's 3.64%, the long-term outlook remains positive, evidenced by a 3-year return of 57.86%.

Are Fermenta Biotec. latest results good or bad?

Fermenta Biotec's latest results show strong year-on-year growth, with a 65.91% increase in net profit and a 37.03% rise in net sales. However, there are concerns as both net profit and sales have declined sequentially for three consecutive quarters, indicating potential challenges in sustaining growth.

Fermenta Biotec's latest results present a mixed picture. On one hand, the company has shown significant year-on-year growth, with net profit increasing by 65.91% to ₹18.88 crore and net sales rising by 37.03% to ₹130.22 crore in Q2 FY26. This recovery is notable given the company's previous struggles with profitability.<BR><BR>However, there are concerning signs when looking at the quarter-on-quarter performance. Both net profit and net sales have declined sequentially, with net profit down 13.51% and net sales down 4.43%. This marks the third consecutive quarter of declining sales, which raises questions about the sustainability of the company's growth momentum.<BR><BR>The operating margin remains healthy at 20.46%, but it has contracted slightly from the previous quarter. Overall, while the year-on-year improvements are commendable, the sequential declines suggest that the company may be facing challenges in maintaining its recovery trajectory. Investors should consider these factors when evaluating Fermenta Biotec's performance.

How has been the historical performance of Fermenta Biotec.?

Fermenta Biotec has shown a recovery in financial performance, with net sales increasing from 335.66 Cr in Mar'24 to 469.48 Cr in Mar'25, leading to a profit after tax of 76.40 Cr, a turnaround from a loss the previous year. However, total expenditure also rose, and cash flow from operating activities decreased.

Answer:<BR>The historical performance of Fermenta Biotec shows a fluctuating trend over the years, with significant changes in net sales, profits, and overall financial health.<BR><BR>Breakdown:<BR>Fermenta Biotec's net sales increased from 335.66 Cr in Mar'24 to 469.48 Cr in Mar'25, marking a notable recovery from previous years. The total operating income followed a similar trend, rising to 469.48 Cr in Mar'25 from 335.66 Cr in Mar'24. However, total expenditure also increased, reaching 359.68 Cr in Mar'25, up from 308.15 Cr in Mar'24. This led to an operating profit (PBDIT) of 121.62 Cr in Mar'25, a substantial increase from 39.32 Cr in the previous year. Profit before tax turned positive at 83.21 Cr in Mar'25, compared to a loss of 9.87 Cr in Mar'24, resulting in a profit after tax of 76.40 Cr, a significant turnaround from the loss of 24.01 Cr in Mar'24. The company's total assets increased to 585.83 Cr in Mar'25 from 525.83 Cr in Mar'24, while total liabilities also rose to 585.83 Cr from 525.83 Cr, indicating a stable financial position. Cash flow from operating activities decreased to 40.00 Cr in Mar'25 from 105.00 Cr in Mar'24, contributing to a net cash outflow of 10.00 Cr in Mar'25. Overall, the company has shown signs of recovery in its financial performance, particularly in sales and profitability.

Should I buy, sell or hold Fermenta Biotec.?

Is Fermenta Biotec. technically bullish or bearish?

As of November 17, 2025, Fermenta Biotec's technical trend has shifted to a moderate bearish stance, supported by bearish MACD, moving averages, Bollinger Bands, and KST indicators, with the RSI showing no momentum signals.

As of 17 November 2025, the technical trend for Fermenta Biotec has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this conclusion include a bearish MACD on the weekly chart and a bearish reading on the daily moving averages. Additionally, Bollinger Bands and KST are both bearish on the weekly timeframe, further supporting the bearish outlook. The RSI shows no signals on both weekly and monthly timeframes, indicating a lack of momentum. Overall, the technical indicators suggest a negative sentiment in the market for Fermenta Biotec.

Which are the latest news on Fermenta Biotec.?

Why is Fermenta Biotec. falling/rising?

As of 04-Dec, Fermenta Biotech Ltd's stock price is declining, currently at 264.55, reflecting a 1.82% decrease. The stock has underperformed significantly over various periods, with a year-to-date drop of 27.31%, amid weak investor sentiment and lack of confidence in its valuation.

As of 04-Dec, Fermenta Biotech Ltd's stock price is falling, currently at 264.55, which reflects a decrease of 4.9 or 1.82%. The stock has been on a downward trend, having lost 6.4% over the last four days and underperformed its sector by 2.11% today. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>The stock's performance over various periods shows significant declines, with a year-to-date drop of 27.31% and a one-year decline of 32.00%. This poor performance is compounded by weak investor participation, as evidenced by a 19.69% drop in delivery volume compared to the 5-day average. <BR><BR>While the company has reported positive financial results, including a 62.14% growth in net profit and a low debt-equity ratio, these factors have not translated into stock price appreciation. The weak long-term fundamental strength, with an average return on capital employed of only 8.52% and below-par growth rates in net sales and operating profit over the last five years, further contribute to investor concerns. Moreover, the absence of domestic mutual fund investment suggests a lack of confidence in the stock's valuation or business prospects.<BR><BR>Overall, the combination of recent price declines, poor performance relative to benchmarks, and weak investor sentiment are key reasons for the falling stock price of Fermenta Biotech Ltd.